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In pursuit of P2X3 antagonists: novel therapeutics
for chronic pain and afferent sensitization
Anthony P. Ford
Abstract Treating pain by inhibiting ATP activation of
P2X3-containing receptors heralds an exciting new approach
to pain management, and Afferent's program marks the
vanguard in a new class of drugs poised to explore this
approach to meet the significant unmet needs in pain
management. P2X3 receptor subunits are expressed predom-
inately and selectively in so-called C- and Aδ-fiber primary
afferent neurons in most tissues and organ systems, including
skin, joints, and hollow organs, suggesting a high degree of
specificity to the pain sensing system in the human body.
P2X3 antagonists block the activation of these fibers by ATP
and stand to offer an alternative approach to the management
of pain and discomfort. In addition, P2X3 is expressed pre-
synaptically at central terminals of C-fiber afferent neurons,
where ATP further sensitizes transmission of painful signals.
As a result of the selectivity of the expression of P2X3, there
is a lower likelihood of adverse effects in the brain,
gastrointestinal, or cardiovascular tissues, effects which
remain limiting factors for many existing pain therapeutics.
In the periphery, ATP (the factor that triggers P2X3 receptor
activation) can be released from various cells as a result of
tissue inflammation, injury or stress, as well as visceral organ
distension, and stimulate these local nociceptors. The P2X3
receptor rationale has aroused a formidable level of
investigation producing many reports that clarify the
potential role of ATP as a pain mediator, in chronic
sensitized states in particular, and has piqued the interest of
pharmaceutical companies. P2X receptor-mediated afferent
activation has been implicated in inflammatory, visceral, and
neuropathic pain states, as well as in airways hyperreactivity,
migraine, itch, and cancer pain. It is well appreciated that
oftentimes new mechanisms translate poorly from models
into clinical efficacy and effectiveness; however, the breadth
of activity seen from P2X3 inhibition in models offers a
realistic chance that this novel mechanism to inhibit afferent
nerve sensitization may find its place in the sun and bring
some merciful relief to the torment of persistent discomfort
and pain. The development philosophy at Afferent is to
conduct proof of concept patient studies and best identify
target patient groups that may benefit from this new
intervention.
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Introduction
In pharmaceutical terms, we continue to fall short in
addressing the increasing need for novel, effective, safe,
and well-tolerated treatments for chronic pain and related
conditions, despite decades of innovation and effort.
Several classes of pain medicines are currently available,
with each class displaying varied effectiveness for treating
the multiple types of pain conditions. The four major
classes are opioids, NSAIDs (including COX-2 inhibitors),
anticonvulsants, and antidepressants. Additional minor
classes (such as triptans, α2-agonists, and local anaes-
thetics) have more limited and specific uses for certain
(mostly acute) pain or related conditions. The limitations to
clinical effectiveness for the major classes are extremely
well known, and range from abuse liability, respiratory
depression, and constipation (opioids), to gastrointestinal
and cardiovascular harm (NSAIDs), to a myriad of negative
central nervous system (CNS) effects (anticonvulsants and
antidepressants). Added to these are the fundamental issues
of limited efficacy (all classes) or tolerance development
(opioids), and convenience issues such as need for dose
titration (opioids, antidepressants, and anticonvulsants) and
large, frequent doses (anticonvulsants). In all these cases,
the concerns grow over chronic use and associated harm,
and the potential for abuse that together widen the chasm
between demand and available response.
There have been many efforts launched in pharmaceutical
discovery for breakthrough of new analgesics and antihyper-
algesics during the last three decades, but so far, none of these
has delivered on the significant demands for registration, and
thus the unmet need remains poorly resolved. These efforts
have covered a selection of exciting novel chemicals directed
at a range of diverse targets, such as 5-hydroxytryptamine 3
antagonists, tachykinin antagonists (e.g., NK1), calcitonin
gene-related peptide (CGRP) antagonists, transient receptor
potential vanilloid-1 antagonists, cannabinoid agonists, inter
alia, but with little real clinical success, so far. Other relatively
innovative approaches are still being pursued (e.g., channel-
specific and state-dependent inhibitors of sensory pathway
Na+ or Ca2+ channels) but have been notable for substantial
chemical difficulties.
A persistent challenge relates to the type of intervention
sought for management of chronic pain. In contrast to
acute, rapid action analgesia, where the goal is to suppress
the perception of “nociceptive” pain arising from frank
tissue injury (e.g., from acute infections, contusions,
fractures, or surgery), in chronic pain situations, it is the
pain itself that has often become largely pathological. In
that sense, one has to attempt to target specifically the
mechanisms leading to a change from normal to abnormal
sensory perception, i.e., the mechanisms contributing to
wind-up and sensitization that are associated with chronic
and inappropriate sensations of pain to normally non-
noxious or mildly noxious stimuli (allodynia and hyper-
algesia, respectively). By the same token, the clear mandate
is also to leave normal “defensive” pain perception intact
and aim to suppress only those elements that specifically
contribute to sensitization in tissues and organs, assuming
they exist separately. Any treatment that reduces hyper-
algesia but also leaves the individual partially insensitive to
harmful mechanical or thermal insults will quickly erode its
usefulness. By extension therefore, approaches to pain
target discovery based on genetic sensory defects that
produce, for example, congenital insensibility to pain,
would seem a little off the ideal path.
P2 purinoceptor targeting
Medicines' discovery has evolved significantly over the last
20 years, with innovation and clinical differentiation more
important than ever, and “me-too” drugs, formulation
enhancements, and nth generations in class seem to be
facing increasing challenges gaining approval and reim-
bursement. We have failed to reverse the continued decline
in drug approvals—especially for new chemical entities
(NCEs) and new mechanism agents for alleviation of many
troubling chronic symptoms including discomfort and pain.
The promise of genomics did not materialize it seems:
genomic and genetic data, so easy as they are to come by,
are so often examined not as part of a “totality” of
information, but outside of the context of prevailing clinical
physiology, pharmacology, and pathobiology—evolving
knowledge garnered over the decades. Within this chal-
lenging context, the therapeutic targeting of purinergic
signaling represents a rich and underdeveloped area. The
purinergic field did not simply materialize overnight on the
back of technological advances or fashions: it emerged in a
gradual manner, intelligent and controversial, with occa-
sional bursts of discovery. It is founded upon an abundance
of diverse data unfolding over the last 40 years, with many
classical pharmacological underpinnings, fostered by lead-
ing scientists in many countries (see [1]).
ATP is, of course, found abundantly in all tissues and
cells, and seems to be overrepresented in pathological
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milieu, with extensive literature militating towards the
functional relevance of ATP in many disease processes. We
now know that a multitude of cell surface receptors mediates
the signaling functions of nucleotides in essentially every
tissue and cell type, and again their contribution to function
seems to be strongly regulated within pathological situations.
These are the components upon which therapeutic advances
have been often founded—multidisciplinary, form and
function, pertinent to disease, translatable to clinical
science. As such, continued progress in developing
differentiated medicines at P2Y12 purinoceptors, the
first examples of P2 receptor therapeutics, reflect these
components with the successive advancement of thera-
peutically important antiplatelet agents: clopidogrel,
ticlopidine, cangrelor, and ticagrelor. Other P2 receptor
targets will likely be harnessed also for therapeutic
benefit in the coming years.
The targeted inhibition of ATP-gated cation channels,
the P2X receptors, has received significant focus from
academic and pharmaceutical scientists in the quest of
small molecule medicinal candidates, and the status of
advancement—as can be gleaned from the literature and
patents—was nicely reviewed in the recent past [2]. The
P2X7 homotrimeric channel has clearly seen most medicinal
progress, with many pharmaceutical companies successfully
identifying developable small molecule antagonists to target a
variety of inflammatory processes where ATP activation of
immune-derived cells via P2X7 is purported to contribute to
disease and symptom progression [3–5]. Several novel
molecules are reported to have entered clinical studies
(Pfizer's CE-224535; Astra-Zeneca's AZD-9056), with a
small number of studies completed in patients with inflam-
mation (e.g., rheumatoid arthritis (RA), chronic obstructive
pulmonary disease (COPD)). Reports of modest efficacy
have been observed with P2X7 antagonism in RA patients,
which at the very least confirms the persistent presence of
elevated ATP within inflamed joints at levels that must be
fairly high, given the low sensitivity of the P2X7 receptor to
ATP, as compared with other P2X ion-channels [6]; however,
subsequent investigations in RA have apparently failed to
show significant differentiation [7]. Nevertheless, additional
interest in this target remains with among other things an
exciting rationale for treatment of neuropathic pain con-
ditions [8].
Beyond P2X7, there has been significant progress within
the P2X family only in chemical efforts to target specifi-
cally ATP-gated channels that contain the P2X3 subunit,
the P2X3 homotrimeric (P2X3.P2X3.P2X3), and P2X2/3
heterotrimeric (P2X2.P2X3.P2X3) receptors. This review
now focuses on the rationale within a range of important
sensory conditions, as well as the progress made in
advancing novel medicinal candidates as “P2X3 antago-
nists” (i.e., blocking all P2X3 containing-channels), which
have advanced to the level where patient studies are
underway.
ATP and P2X3 relevance to primary afferent signaling
and sensitization: indication rationales
A sensory role for ATP can be traced back over 50 years [9]
to studies showing that ATP released from sensory nerves
during antidromic stimulation caused vasodilation in the
rabbit ear artery. It was considered possible that multiple
purinergic pathways and receptors may be involved in the
sensory actions of ATP; however, since their discovery in
1995 [10, 11], a crucial role has been proposed for
receptors containing P2X3 subunits (homotrimeric P2X3
and heterotrimeric P2X2/3 receptors) in mediating the
primary sensory effects of ATP [12–14]. P2X3 and P2X2/
3 receptors are predominantly localized on small-to-
medium diameter C- and Aδ-fiber sensory neurons within
the dorsal root ganglion (DRG) and cranial sensory ganglia
[15–17], and on their peripheral nerve terminals in
receptive fields in tissues including the skin, joints, and
viscera (Fig. 1). P2X3 and P2X2/3 receptors are also
present on the central projections of these primary sensory
neurons within the dorsal horn of the spinal cord and in the
brainstem, where they apparently play a role in augmenting
release of glutamate (as well as substance P) at this first
sensory synapse [18–22]. Beyond these cellular locations,
expression of P2X3 subunits appears to be somewhat
sparse, with reports implicating certain epithelial cell
populations (e.g., within the urinary bladder) and brainstem
neurons as hosts, though with limited functional corollary
described so far [23, 24].
Data supporting a therapeutic potential of selective
antagonism of P2X3 containing receptors covers many
investigational approaches: distribution of receptor subunit
RNA and proteins; results from gene-targeting methods in
mice and rats and studies of novel antagonists in preclinical
rodent models; observations from human investigations of
ATP content of pathological fluids and samples; expression
of P2X3 immunoreactivity and studies of the effects of ATP
itself in healthy volunteers or in isolated tissue samples.
The range of potential therapeutic opportunities covers
essentially any condition wherein chronic dysregulation and
sensitization of populations of sensory neurons has been
implicated, including inflammatory, visceral, neuropathic
and cancer pain, as well as many conditions where
bothersome “irritative” symptoms surface from similar
chronic sensitization of afferent pathways (e.g., overactive
bladder, irritable bowel syndrome, chronic itch and cough,
and airways hyperreactivity). The evidence category that
now remains is the key one: what effects are observed in
clinical studies using chemical antagonists for P2X3
containing receptors? Clinical findings to date from studies
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with AF-219 (the only antagonist known to advance to
human studies) have not been published, but in due course
this dearth of information will change significantly.
A selection of reports over the last 40 years indicated the
direct involvement of ATP in the perception of pain,
including the early clinical demonstration that ATP applied
to a blister base in healthy human volunteers was associated
with heightened pain sensation [25–27]. ATP applied to
forearm skin by iontophoresis also caused mild painful
responses that were enhanced by sensitization with UV
irradiation or intradermal capsaicin [28]. Intracutaneous
injection of ATP [29], or its direct infusion into skeletal
muscle [30], also caused significant pain in human
volunteers. Subsequent studies in animals using more
selective pharmacological and gene-based tools fortify the
link between these effects and a crucial role for P2X3 and
P2X2/3 receptors. Using the P2X1, P2X3, and P2X2/3
selective antagonist 2',3'-O-(2,4,6-trinitrophenyl)-ATP
(TNP-ATP) [31–35], and the P2X3, P2X2/3 selective
antagonist A-317491 [36, 37], many investigators have
shown that peripheral and spinal P2X3 and P2X2/3
receptors are involved in persistent, chronic neuropathic
and inflammatory pain. Mice deficient in P2X3, P2X2, or
both receptor subunits [38–40], as well as animals treated
with P2X3-selective antisense [34, 41, 42] or short interfering
RNA (siRNA) [43] revealed comparable findings. Collec-
tively, these data have elucidated P2X3 as the principal
substrate connecting ATP with chronic sensitization, espe-
cially in the context of injury and inflammation, yet, notably,
with no clear evidence for involvement in the acute
(defensive) sensation of noxious stimuli. Thus, a proposition
that antagonism of P2X3 and/or P2X2/3 receptors may have
potential therapeutic utility in the management of chronic
pain conditions is reasonable. The following sections provide
an overview of several indication areas where data provide
strong clues to potential utility.
Inflammatory, joint, and musculoskeletal pain
ATP has a broad range of activities in inflammatory pathways,
and through many different cell types and receptors that have
been implicated in chronic inflammatory diseases [44–46].
However, evidence for inflammatory cell P2X3 receptor
expression or activation by ATP is not readily apparent, and
while sensory axon reflexes following activation of primary
afferent neurons may give rise to release of factors (e.g.,
prostanoids, substance P or CGRP) that could contribute to
or modulate neurogenic inflammatory responses, there is little
evidence available specifically. Two reports have described
possible functions of P2X3 receptors in activation of
inflammatory and trophic responses in chondrocytes and
synovial fibroblasts in joints [47, 48] but with no in vivo
correlate, and thus there is little clear evidence that
underlying joint disease progression is under the influence
Fig. 1 P2X3 containing iono-
tropic receptors are found in a
large proportion of unmyelinated
and thinly myelinated primary
afferent nerves innervating essen-
tially all tissues and organs. ATP
is released from many cell types
in these receptive fields, as well as
at the central terminals of
activated afferents, and more so
under conditions of injury,
inflammation, stress, movement,
and distension. Afferent sensiti-
zation results and appears to
contribute to the serious symp-
toms of acute and chronic pain
and irritation in musculoskeletal,
visceral and neuropathic sensory
disorders
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of P2X3. In the context of symptom modification however,
what happens to sensory responsiveness in tissues in models
of chronic irritation or inflammation has been well studied,
and there is clearly potential for utility of P2X3 antagonism
in inflammatory pain conditions, including those in the
musculoskeletal systems [36, 49–51].
Increased P2X3 receptor expression and function have
been reported in several rodent joint models typified by
application of noxious irritant substances or mechanical
damage to paw, knee, vertebral, or temporo-mandibular
sites [49–52]. Complete Freund's adjuvant (CFA), formalin,
carrageenan, and mono-iodoacetate (mIOA), when injected
acutely each gives rise to development of pain-related
(nocifensive) behavior in rodents, such as reduced tolerance
thresholds to mechanical and thermal provocation, reduced
weight-bearing activity, as well as complex behaviors more
relevant to emotional and cognitive responses to pain
perception [53]. In these models, P2X3 receptor mRNA
or expression are elevated in small- and medium-sized
neurons in associated dorsal root or cranial ganglia, as well
as in both the peripheral terminal fields in the joint and/or
central terminals in dorsal horn of spinal or brainstem
projections. Knock-out (KO) mice with deletions of P2X3,
P2X2 and both receptor subunits showed reduced response
to formalin injection into the paw [38, 39], while rats
treated intrathecally with both antisense oligonucleotides as
well as siRNA probes showed considerable reductions in
mechanical and thermal hyperalgesia in classical paw or
knee joint irritation models [34, 41, 43].
ATP content may also be elevated in inflamed or
damaged tissues and joints [54] (Fig. 2), is able to activate
arthritic knee-joint afferent fibers [55] and is present in
arthritic patient synovial fluid [56, 57] as well as at tumor
sites [58]. Recently, it was reported that in patients with
arthritic knee joints [59], synovial ATP content was both
positively associated with symptom severity and seen to
decline during symptom ameliorating therapy with intra-
articular hyaluronic acid.
Pharmacological approaches have been broadly used in most
types of inflammatory and joint irritation models, and shown
effective reduction in mechanical and thermal hypersensitivity
following use of prototypic (non-specific) antagonists
Fig. 2 Pain from damaged and
strained joints and other muscu-
loskeletal structures chronically
impacts the lives of a vast
number of individuals. Available
pain medicines are often inade-
quately effective, poorly tolerat-
ed or considered unsafe,
highlighting the great demand
for medicines with novel mech-
anisms of action. P2X3 antago-
nists have shown to be effective
in reversing hyperalgesia in
several animal models of joint
pain, and in studies of pain from
cancer invasion of bony tissues.
Osteoarthritis of the knee, an
exceptionally common condi-
tion, is one of several high
potential indications for novel
P2X3 antagonists
Purinergic Signalling (2012) 8 (Suppl 1):S3–S26 S7
(pyridoxal-phosphate-6-azophenyl-2′,4′-disulfonate (PPADS),
suramin), selective polyanionic antagonists (TNP-ATP,
A-317491) as well as novel selective drug-like antagonists.
The most extensive examinations have utilized the tricarbox-
ylic acid P2X3 antagonist A-317491, which due to its
restricted permeability is useful for investigation following
various parenteral routes of administration. On peripheral
administration, A-317491 can access vascular compartments
and thus peripheral tissues and imparts action at receptive field
terminals for P2X3 containing neurons. It is possible that
following such routes, the antagonist may also have the
potential for action at sensory cell bodies in the ganglia (DRGs
and cranial sensory ganglia), as well as other peripherally
located cell types that may contain P2X3 (e.g., synoviocytes,
bladder epithelium); little or no CNS penetration is likely, so
central terminal P2X3 receptors are uninfluenced. On local
administration (e.g., intraplantar or intravesical), high con-
centrations can be achieved in specific target receptive fields,
but access beyond such sites (especially to ganglia or dorsal
horn termini) will be negligible. After intrathecal delivery,
activity would reflect antagonism of P2X3 containing
receptors on central projections of afferent neurons within
dorsal horn laminae and central brainstem projections of
cranial sensory neurons. In an excellent overview,
McGaraughty and Jarvis [49] described that A-317491
produced antihyperalgesic effects to mechanical and
thermal stimuli, with greatest effect after systemic appli-
cation, with local (intraplantar) and central (intrathecal)
delivery producing smaller and less consistent effects.
Thus, antihyperalgesic effect can arise at multiple points
on the primary relay, and penetration of blood–brain
barrier may increase effect magnitude.
A rodent model often employed for assessing potential
for drug effect in osteoarthritis (OA) pain is based on
intraarticular injection of monoiodoacetate (mIOA) into one
knee joint of the rat. mIOA inhibits glyceraldehyde-3-
phosphate dehydrogenase activity in chondrocytes, disrupts
glycolysis, and leads to cell death [60]. Progressive loss of
chondrocytes leads to histological changes of the articular
cartilage over subsequent weeks that resemble the changes
which occur in human OA, leading to joint discomfort
exemplified by a shift in the weight distribution (asymme-
try) to favor the unaffected limb. The selective and “drug-
like” P2X3 antagonist AF-353 [61] has shown robust
efficacy in this model of OA as well as in the classical
adjuvant arthritis model of joint hyperalgesia, based on
intraplantar CFA administration. In Fig. 3a, b, data are
shown from a study where 7d prior intraplantar CFA led to
Fig. 3 Nocifensive data showing the effect of a P2X3 antagonist in
preclinical models of joint hyperalgesia. a In an adjuvant-induced
arthritis model in rat (7d following intraplantar administration of
complete Freund's adjuvant), AF-353 produces dose-dependent anti-
hyperalgesia in weight-bearing asymmetry and von Frey filament
mechanical tests; magnitude of effect is compared with that of the
NSAID naproxen. b In a rat model of knee osteoarthritis (14d
following intra-articular administration of monoiodoacetate), AF-353
produces dose-dependent anti-hyperalgesia in weight-bearing asym-
metry test (left; compared with the COX-2 inhibitor Vioxx). In the
same model, following repeated dosing, AF-219 (7d bid, orally; right)
attenuates the weight bearing laterality with complete reversal of
apparent hyperalgesia at the two higher doses
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mechanical hyperalgesia against which AF-353 produced
dose-dependent reversal in both weight-bearing and von
Frey filament tests of hyperalgesia (equivalent efficacy
compared with the NSAID naproxen). In Fig. 3c, d, (Knee
mIOA model, 14d prior intra-articular mIOA) acute oral
administration of AF-353 produced dose-dependent anti-
hyperalgesia in weight-bearing asymmetry (higher effi-
cacy compared with a clinical relevant dose of rofe-
coxib), while the closely related antagonist AF-219
(after 7d bid, po dosing at 6, 20, and 60 mg/kg) fully
reversed weight bearing laterality at 1.5 and 3.0 h after
the final dose.
Most recently, reports emerged from rodent models
associated with significant cancer cell invasion, usually to
bone or cutaneous sites, modeled as surrogates for bone or
soft tissue metastasis pain, wherein lytic cancer cells are
carefully implanted into the large bones such as tibia or soft
tissues such as gingiva. The erosion and inflammation
causes significant change in sensory innervation to the
affected area [62, 63] with P2X3 expression and function
increased within these receptive fields and in adjacent
overlying tissues [64, 65]. Consistent with this, antagonism
of P2X3 receptors (using AF-353 or A-317491) has been
shown independently by at least two groups to acutely
reverse and chronically delay progression of development
of tactile allodynia/hyperalgesia and/or raise weight-bearing
thresholds [66, 67]. Figure 4 illustrates such data from a
tibial invasion model, with significant effect produced by
AF-353, given orally (twice daily), when given either
during (preventative) or following (reversal) development
of hyperalgesia.
While the relative contribution of central versus periph-
eral terminal P2X3 antagonism has been somewhat
addressed in inflammatory and urological models, one
aspect that has not been well addressed is whether the
effects seen with various antagonists requires blockade of
P2X3 homotrimers alone or P2X2/3 heterotrimers in
addition. From studies using TNP-ATP, A-317941, AF-
353, it is not easy to answer this question, as the antagonists
block homo and heterotrimeric P2X3 receptors, albeit with
slightly higher concentrations needed for the latter. In a
recent report [68], scientists at AstraZeneca described
findings with a novel antagonist (AZ004, a pyrrolopyrimi-
dinone) which shows apparently high potency for inhibition
of rat and human P2X3 (IC50 values 13–30 nM) while
showing no activity at P2X2/3 heterotrimers at up to 2 μM
(rat) or 10 μM (human). After subcutaneous administration,
AZ004 was able to produce potent inhibition of paw
mechanical hyperalgesia in rats pretreated with intraplantar
CFA, which was reproduced by direct intraplantar, but not
intrathecal injection of the antagonist. It remains open for
confirmation whether this significant impact via peripheral
P2X3 homotrimer blockade is unique to this particular
model system or relatively general to these types of
inflammatory models.
Collectively, while recognizing that any attempt to
accept data from an animal model as predictive for human
disease and discomfort is rash, the weight of evidence from
a wide range of irritative and inflammatory models of
musculoskeletal hyperalgesia make pretty reasonable the
proposition that P2X3 antagonists should be assessed in
chronic conditions such as in OA and RA, joint and muscle
contusions and sprain, and even in chronic and break-
through pain in patients with cancer.
Visceral pain
ATP regulation of sensory perception and pain in visceral
structures has been described for a variety of organ systems,
and forms a key component of Burnstock's unifying
purinergic proposition relating to mechanosensation and
control of movement and secretion in hollow organs (the
“tubes and sacs” hypothesis; [69, 70]). It is suggested and
with significant supportive evidence, that ATP, released
from epithelial cells lining the bladder (Fig. 5), ureter, and
gut during distension (though likely also from other cell
types including smooth muscle), acts on P2X3 and/or
P2X2/3 receptors on lumbosacral (pelvic) and thoracolum-
bar (splanchnic) subepithelial sensory nerve terminals to
relay messages about stretch, pressure, irritation via sensory
ganglia and spinal cord to pain centers in the CNS [70, 71].
Under chronic conditions of inflammation or injury,
sensitization of these afferent pathways accompanies
upregulation of expression of these receptors. In animal
models and clinical investigations, evidence has also
surfaced showing concomitantly increased local ATP
concentrations, and P2X3 expression is also elevated in
specimens from clinical bladder and gut pathologies
[72–74].
Afferents fibers chemically traced from bladder, ureter,
bowel, or esophagus show P2X3 expression and sensitivity
to activation by ATP in high proportions (often >50%; [70,
71, 75]). Among these organs systems, the greatest
attention has been placed on urinary tract, the role of
ATP/P2X3 within the urinary sensory limb, and its
contribution to storage and elimination reflexes in normal
conditions and in disease. P2X3 and P2X2 subunit gene
deletion in mice (either as single knock-outs or cross-bred
double-KO mice) produced alteration in bladder reflexes
(hyporeflexia) with considerable elevation of bladder
volume thresholds [38, 39]) under conditions that expose
C-fiber pathways. Greatly reduced firing from isolated
bladder and ureter afferents in response to distension was
also seen in these KO mice [76–78].
Selective P2X3 antagonists do lower urinary overactivity
in disease models, the earliest such report examining the
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Fig. 4 Systemic P2X3 receptor antagonism with AF-353 attenuates
bone cancer pain behaviour in rats. Intra-tibial injection of MRMT-1
carcinoma cells (black circle) induced significant increases in both
mechanical allodynia (a and c) and weight-bearing difference (b and
d) compared with the control rats (yellow square and open triangle).
Oral administration of AF-353 (bid) significantly attenuated both
MRMT-1 carcinoma cell-induced mechanical allodynia and weight-
bearing difference when given before development of bone cancer
pain behavior (termed prophylactic treatment, red circle), while bone
cancer-induced established mechanical allodynia could be signif-
icantly reduced by AF-353 (termed reversal treatment: diamond).
The red and blue bars represent the prophylactic and reversal
treatment dosing periods, respectively. Mechanical allodynia was
quantified by calculating the area under the curve values determined
from a plot of the percentage of positive ipsilateral withdrawal
response at each filament against the filament force on a logarithmic
scale. Hindlimb weight-bearing difference was expressed as contra-
lateral minus ipsilateral readings. Values are expressed as means±
SEM. **P<0.01 and ***P<0.001 versus the cancer+vehicle group
(from [66]). In the lower panel (e) is shown immunohistochemical
characterization of the retrogradely labeled Fast Blue DRG neurons
innervating the rat tibia. Fast Blue (blue) labeling was present in
both P2X3- (green) and calcitonin gene-related peptide (CGRP)-
positive (red) neurons at the L2 and L3 DRG levels
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effects of intravenous administration of A-317491 in a rat
spinal cord injury model [78–81]. The antagonist produced
a dose-dependent inhibition of non-micturition bladder
contractions, increased inter-micturition interval, and blad-
der capacity, without influencing the amplitude of voiding
contractions. This pattern of effects may seem fairly
desirable if translated into a clinical setting, where
inappropriate sensitivity to low volume filling, with
exaggerated urinary frequency and sense of urgency could
be suppressed while leaving untouched the force of detrusor
contraction needed to maintain voiding efficiency. The
relevance of the spinal transection model for human disease
can be debated, but one of the purported consequences is
that descending inhibitory pontine control of voiding
reflexes is severed and so local segmental (“reflex bladder”)
C-fiber driven circuits become unmasked. This model is
also associated with increased ATP liberation from bladder
epithelial cells and increased levels of ATP in the dorsal
horn of the lumbosacral spinal cord [82–84]. A-317491 was
also studied in a cystometric model in rats pretreated
(2 days prior) with cyclophosphamide [85] to produce an
inflammatory urinary hyperreflexia. Similar responses were
seen as in the spinal model, with increased intervals
between voids, reduced non-micturition bladder contrac-
tions and amelioration of cyclophosphamide-induced resid-
ual volumes, all without impact on the amplitude of voiding
contractions.
The diaminopyrimidine AF-353 was studied in a closed
cystometric model (“refill VIBC”) in a urethane-
anesthetized rat with a dose-dependent increase in volume
threshold by up to 50–70%, with frequency slightly
reduced, but no appreciable change in amplitude (see
Fig. 6a; [86]). As AF-353 penetrates the blood–brain
barrier [61], it is not clear whether these effects resulted
from P2X3 antagonism at peripheral terminals within the
bladder wall, or alternatively at central terminals in the
spinal cord dorsal horn, where is has been shown that ATP
is released and can act on P2X3 receptors to enhance
central glutamate transmission [18, 83, 87]. Two separate
studies using distinct members of the diaminopyrimidine
class helped to address the question of central versus
peripheral mode [86, 88]) and it was seen that presynaptic
Fig. 5 Sensory fibers in visceral
organs, especially the urinary
bladder, express high levels of
P2X3 receptors that are elevated
in pathological conditions;
unmasking segmental spinal
reflexes that sense ATP content
during filling and distension.
P2X3 antagonists suppress af-
ferent excitation and raise filling
volume thresholds, especially in
rodent models of cystitis. The
distressing and largely unmet
painful and irritative symptoms
of bladder pain syndrome/inter-
stitial cystitis and chronic pros-
tatitis as well as lower urinary
tract symptoms (urgency, fre-
quency, and nocturia) associated
with overactive bladder and
benign prostatic hyperplasia,
represent important visceral
indications for novel P2X3
antagonists
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P2X3 and/or P2X2/3 receptors on the central terminals of
bladder primary afferents were able to facilitate both normal
and noxious input from the micturition reflex. In Fig. 6b,
recording of action potential discharge from pelvic afferents
in an isolated bladder model from cyclophosphamide
treated rats is shown, in which AF-353 applied either to
the extraluminal or intravesical fluid is able to markedly
suppress activity in response to filling. Whether the
potential for therapeutic impact in urinary tract disorders
such as overactive bladder (OAB), benign prostatic hyper-
plasia, lower urinary tract symptoms (LUTS), bladder pain
syndrome (BPS)/interstitial cystitis (IC), or renal/ureteric
colic requires blockade of peripheral, central, or all P2X3-
containing receptors will be a matter for further exploration.
Nevertheless, this range of activities seen in urological
models offers a reasonable foundation for P2X3 antagonist
investigation in clinical conditions associated with LUTS
and pain (e.g., OAB, BPS, chronic prostatitis). Generaliza-
tion of these mechanistic findings across other hollow
organs has been reported [89–91] and accordingly invites
consideration of antagonist utility in functional gut disor-
ders such as irritable bowel syndrome; it seems also clear
that cross-sensitization (viscero-visceral and viscero-
somatic) is an important topic in pain syndromes and this
may become a valuable focus [92, 93].
Neuropathic pain
The evidence for P2X3 contribution to development of
neuropathic pain in models was not initially considered
strong, based on protein expression data, but over the last
decade it has grown markedly especially on the basis of
functional animal data examining modulation of developed
hyperalgesia and allodynia. Bradbury et al. [16] had shown
that P2X3 receptors in DRG and dorsal horn are down-
regulated following peripheral nerve injury (sciatic axot-
omy) but that their expression can be up-regulated by
concurrent glial-derived neurotrophic factor (GDNF) expo-
sure. However, Eriksson et al. [94] demonstrated that
ligation/section or chronic constriction of the mandibular
inferior alveolar nerve led to significant upregulation of
P2X3 immunoreactivity in trigeminal ganglia and in
associated nerve endings. Similarly, Novakovic et al. [95]
studied P2X3 purinoceptor cellular distribution in rat
sensory ganglia and dorsal horn in naive animals and
following peripheral nerve injury (sciatic chronic constric-
tion injury (CCI) model) using immunohistochemical
methods. Two to four weeks following unilateral CCI, the
number of P2X3 positive small and medium diameter
neurons increased in DRG, and expression levels were
higher in spinal cord on the side ipsilateral to the ligated
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Fig. 6 Effects of P2X3 antago-
nists in preclinical models of
urinary bladder reflexes. a P2X3
antagonism (AF-353) signifi-
cantly raises volume thresholds
and lowers frequency of mictu-
rition reflexes in filling cystom-
etry models in rats anesthetized
with urethane, which unmasks
segmental spinal pathways. b
Bladder–pelvic nerve prepara-
tion from cyclophosphamide
(CPM) sensitized rats. Afferent
nerve firing associated with
volume expansion is markedly
reduced by P2X3 antagonism
with AF-353, applied either to
serosal (extraluminal, left) or
intravesical (intraluminal right)
surface of the bladder (figures
kindly provided by Prof Wei-
fang Rong, Shanghai Jiaotong
University, China)
S12 Purinergic Signalling (2012) 8 (Suppl 1):S3–S26
nerve, consistent with up-regulation of receptors in presyn-
aptic terminals of the primary sensory neurons. Since then,
several reports have surfaced that essentially corroborate
the findings of Novakovic et al. [95] in CCI and ganglion
compression models of sciatic and trigeminal nerves [52,
96–100], and a single report has examined a clinical
neuropathic pain condition [101] and shown upregulation
of P2X3 neuronal expression.
These findings differed not only from those reported
by Bradbury et al. [16] but also by Kage et al. [102]
where following L5/L6 spinal nerve ligation the propor-
tion of small-diameter neurons expressing P2X3 was
reduced, although P2X3 immunoreactivity of medium-
sized neurons in the L5 and L6 DRG was unchanged.
Other recent studies have also shown either a down-
regulation of P2X3 in the plantar dermal receptive field
following sciatic CCI [103], a transient reduction in
trigeminal P2X3 expression in model of partial injury of
the mental nerve [104] or no change in P2X3 expression
following lingual nerve section [105]. Exactly why this
varied picture developed is not very clear, but it is possible
that these discrepancies reflected a distinction in upward
regulation of P2X3 expression following a constriction
injury (loosely applied ligature and therefore non-
axotomic) compared with reduction or no change follow-
ing more extensive nerve injury or complete axotomy,
where receptor loss may be expected. Thus, a key factor
would be to differentially examine P2X3 expression in
neurons that remain intact in axons or ganglia after
traumatic intervention. Such an investigation was per-
formed in one study [106], though looking at P2X3
mRNA rather than protein in DRG and trigeminal ganglia
following tibial plus common peroneal transection or
infraorbital nerve transection, respectively. These authors
found that P2X3 mRNA in ATF3-immunoreactive neurons
decreased significantly after injury, indicating that axo-
tomized neurons lost P2X3 mRNA, despite an overall
increase in P2X3 mRNA relative to the total number of
sensory ganglion neurons. It was suggested that P2X3
mRNA expression increases in intact neurons and that P2X3
mRNA in intact neurons may contribute to the sensory
changes post nerve-injury in primary sensory neurons. Similar
observations were made in a recent report [104] in rat skin
sensory nerves following partial loose ligation injury of the
mental nerve, a purely sensory branch of the trigeminal nerve
that innervates the lip. Most importantly, these authors
tracked P2X3 expression in dermal and epidermal neurons
following injury at multiple time points, and showed that a
transient decrease in expression occurred over 2 weeks,
followed by increases in subsequent weeks, which followed
expression changes in GDNF in the skin, and also tracked
with changes in markers of sympathetic and parasympathetic
axon sprouting in the same receptive areas. Thus, timing of
assessment of receptor regulation is critical and could
account for mixed observations reported.
Despite a varied picture in protein expression studies in
neuropathic models, a more consistent and positive picture
has emerged in functional investigations of neuropathic
hyperalgesia. Thus, using antisense and RNAi knockdown
probes to suppress P2X3 expression following nerve injury
[34, 41, 43], sensitization to tactile and thermal stimulation
was reduced. Likewise, in several pharmacological studies
in neuropathic pain models, reports have indicated increased
sensitivity to ATP and analogs in sensitized neurons [52, 100,
107–110] or that selective antagonists, including A-317491
and AF-353, can reverse central sensorineuronal wind-up
[111] or hypersensitivity to tactile stimulation [36, 37, 49],
with evidence for effect dependent on a combination of
peripheral and central actions.
The reports above offer justification for investigation of
P2X3 antagonism in clinical neuropathic conditions, such
as post-herpetic neuralgia (PHN), diabetic peripheral
neuropathy (DPN), trigeminal neuralgia (TGN) and radi-
culopathy, although the concerns over patient heterogeneity
(especially in DPN), and the questionable “face-validity” of
neuropathic pain models remain clear. Such trials have
generated more than their fair share of study failure and
make one pause for thought about the best approach to
clinical assessment.
Airways hyperreactivity
P2X3-containing receptors are expressed by a large
proportion of C- and Aδ afferents that innervate the upper
and lower airways arising from both placodal (nodose) and
neural crest (jugular) ganglia [112, 113]. Earlier data on
airways P2X3 had been mostly immunohistochemical (e.g.,
[114]), but more recently, data-driven arguments have
surfaced [115] in favor of the proposition that afferent
sensitization may drive a significant a component of key
airway dysfunctions, signs, and symptoms (e.g., bronchial
hyperreactivity, hypersecretion, cough, dyspnea; Fig. 7),
with more attention placed on the possible role of P2X3
receptors. There are now several relevant reports that
indicate P2X3 antagonism as an approach to reducing such
airways sensitization.
In the primary model of cough used preclinically, in
which aerosolized citric acid induced cough in guinea pig,
it has been shown that ATP enhances citric acid cough, and
that available P2X receptor antagonists block this effect in a
manner consistent with involvement of P2X3 containing
receptors [116]. In the same model, cough evoked by citric
acid is also augmented by co-application with histamine,
and this effect can also be significantly inhibited by P2X
receptor antagonism, consistent with the effect of histamine
being mediated via release of ATP within the lungs [117].
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The characterization of the specific P2X receptor(s)
involved is a little ambiguous, hampered by lack of specific
probes, but is not inconsistent with P2X3 receptor
involvement.
It is now established that P2X3 containing receptors are
significantly involved in activation of vagal C-fibers and
rapidly adapting receptors (Aδ-fibers) that are believed to
be central to cough initiation and sensitization [113]. Using
one of the first selective P2X3, P2X2/3 antagonists, the
tricarboxylic acid A-317491 (Abbott), it has been shown
that ATP activation of airways afferents was indeed
mediated by P2X3 containing receptors [112]. Moreover,
electrophysiological recordings from jugular and nodose
afferents of guinea pig airways confirm that ATP acting via
P2X2/3 heterotrimers in nodose fibers leads to action
potential initiation [112]. More recently, an intermediary
role for ATP linking bronchoconstriction with firing of
airways sensory fibers has been mechanistically investigat-
ed, and P2X3 receptors (probably via P2X2/3 hetero-
trimers) clearly mediate bronchospasm induced afferent
nerve activation in isolated perfused lung/vagus nerve
preparations from guinea pig (Fig. 8; [118]).
In other investigations, it has been shown that
extracellular ATP activates canine and rodent pulmonary
vagal sensory fibres (Aδ and C), which then leads to
neurogenic bronchoconstriction and cough [119]. ATP
administered by aerosol inhalation in humans induces
several airways effects including cough, bronchospasm,
dyspnea, and tightness in asthmatics and effects are
greater than seen in healthy controls, with significantly
greater potency to ATP than for adenosine and AMP, the
latter indicating that the effects are not primarily mediated
via degradation products of ATP [120]. Additionally, it is
reported that intravenous infusion of ATP in pre-terminal
cancer patients gives rise to highly distressing symptoms
of breathlessness, chest tightness, and dyspnea in a large
number of subjects [121].
Finally, adding further support of the potential for ATP
involvement promoting respiratory disease and dysfunction,
it was recently shown that the concentration of ATP is
Fig. 7 Airway sensitization and
irritation. Large proportions of C
and Aδ fiber afferents in the
upper and lower airways express
P2X3 receptors and can be
sensitized by ATP. Activation of
some of these sensory nerves by
ATP liberated from epithelial
and smooth muscle cells is
postulated to contribute to com-
ponents of airways hyperexcit-
ability, giving rise to airways
hypersecretion, bronchospasm,
breathlessness (dyspnea), and
chronic cough, all of which are
undermanaged factors in chronic
diseases such as COPD and
asthma
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markedly elevated in the bronchoalveolar lavage fluid from
COPD patients, with smoking exacerbating the ATP
elevations and concentrations showing marked correlation
with increased obstructive measures and symptoms [122,
123]. In this study, it was concluded that “COPD is
characterized by a strong and persistent upregulation of
extracellular ATP in the airways” and although the authors'
focus was on the contribution of extracellular ATP to the
pathogenesis of COPD (by promoting inflammation and
tissue degradation, purportedly through P2X7 activation),
the likelihood that afferent sensitization induced by avail-
able ATP heightens symptomatic manifestations, morbidity,
and mortality should not be overlooked. Therefore, the
management of critical airways disease characteristics and
symptoms of bronchospasm, hypersecretion, cough, and
dyspnea that are very poorly met with existing therapy in
chronic asthma and COPD represents a possible target for
P2X3 blockade.
P2X3 antagonists: additional therapeutic avenues, safety,
and tolerability
The sections above cover areas where the supportive data
for P2X3 antagonism have been most abundant. Clearly,
the need now is for focused clinical studies, as animal
models, useful as they are, are far from optimal representa-
tions of clinical syndromes and distressing symptoms. What
seems apparent considering the rationales detailed above is
that P2X3 antagonism has a uniquely broad range of
activities across visceral, inflammatory and neuropathic
models, whereas most of the major analgesics are less
broadly active across models.
There are other sensory systems that are worthy of
mention, studied in the context of P2X3 activity, though
in many cases without the benefit of selective inhibitors,
and relying more heavily on gene or protein expression
data or studies using non-specific probes. These reports
offer bases for additional rationales for P2X3 antagonist
potential; likewise, it also has to be considered that
some activities of P2X3 containing receptors may
contribute to important physiological functions, and that
their antagonism may lead to clinically significant
adverse events that affect tolerability or safety in some
patient groups, and that may weaken the potential
clinical effectiveness of the class overall. In the
following section, such considerations are discussed.
In the largest sensory organ, the skin, it is quite apparent
that the expression levels of P2X3 receptors (possibly more
often as homotrimers) and levels of C-fiber activation by
ATP are high [75] and represented on several distinct
subgroups of fibers. A specific population of so-called
tactile C-fibers has been identified in rodents that express a
particular subtype of the Mrgpr receptor family (mas-




Fig. 8 a, b Extracellular recording of action potential discharge from
an intrapulmonary nodose C-fiber in an ex vivo isolated, perfused
lung-nerve preparation from guinea pig. a Representative recording of
action potential discharge from a single lung nodose C-fiber
(conduction velocity 0.78 m/s) in response to histamine (HA,
30 μM) delivered as a 1 ml bolus injection into both the pulmonary
artery and the trachea. b Perfusion of the same C-fiber with AF-353
(100 μM, 15 min) reduced both the peak frequency of action potential
discharge and the total number of action potentials (AP) generated in
response to HA by 64% (figures kindly provided by Prof Brad
Undem, Johns Hopkins University, USA). c Effect of TNP-ATP on the
histamine-induced increase in the number of citric acid-induced
coughs in guinea pigs. The guinea pigs were exposed to 0.6 mM
histamine aerosol for 2 min during the 5 min preceding the inhalation
of 0.1 M citric acid. Guinea pigs were exposed to TNP-ATP or
reactive blue 2 (RB2) for 2 min during the 5 min preceding the
inhalation of histamine. The number of coughs during 10 min of
exposure to citric acid was counted before (open column) and after
exposure to histamine (hatched column). Each column represents the
mean with S.E.M. for five animals. *P<0.05 vs. the value before
exposure to histamine. #P<0.05 vs. the value after exposure to
histamine of saline-treated guinea pigs (reproduced with permission
from [117])
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related G-protein coupled receptors; also previously
reported as sensory neuron-specific receptors, SNSR; see
[124, 125]: these are the MrgprD C-fibers (or MrgD fibers),
which unlike the MrgA, B or C groups, are subject to
persistent expression of the runt domain transcription
factor, Runx1 [126]. MrgD afferents make up ∼60% of
the epidermal innervation [125] and in particular innervate
the outermost of the four layers of epidermis, the stratum
granulosum. Notably, classical C-fiber sensitizers such as
capsaicin, serotonin, protons, nicotine, menthol, peptides
(CGRP, substance P) do not activate MrgD fibers, but they
are sensitive to ATP, and respond with kinetics that are
consistent with the P2X3 homotrimer [127]. The implica-
tion is that these afferents, sitting closest to the external
environment, are sensitive to ATP presumably released by
mechanical activation of keratinocytes and brushing of hair
fibers, though it is certainly not yet clear whether these are
nociceptors or perhaps lower threshold mechanosensors, or
function with broad dynamic range contingent on trophic
factor interplay.
It remains unclear whether human cutaneous afferents
are similarly organized, though sensitivity to ATP has been
clearly shown to injection, iontophoresis and blister
application (as discussed above). It is possible that MrgD
afferents correspond to the so-called C-tactile fibers that are
found only on hairy skin and are responsive to gentle
stroking evoke pleasurable or “hedonic” tactile sensations
[128, 129]. Antagonism here may remove a potentially
pleasurable social response, unlikely though this would be a
major issue to drug tolerability. On the other hand, it should
be considered that in chronic painful conditions, especially
neuropathic injuries such as in shingles, post-herpetic and
trigeminal neuralgia, and in more subchronic hypersensiti-
vies such as following burn injury [130, 131] or even
sunburn [28, 132], the phenotypic sensory change is such
that mild tactile stimulation and stroking can now be
perceived as highly painful in the affected dermatome, and
accordingly there may be significant anti-allodynic benefit
to P2X3 antagonism, with the potential even for topical
application. A further potential area for consideration,
though again inadequately investigated, is the potential that
hypersensitivity in these afferent populations may have any
bearing on conditions associated with persistent and
troublesome itch (or indeed the perceived benefit and
transient relief of a good itch-induced scratch), though in
the context of these C-fiber populations, there has been no
evidence presented.
Just as ATP and P2X3 receptors seems to be a key part
of the primary mechanical sensing system in the superficial
layers of the skin, ATP signaling also occurs in the special
senses, participating in the perception of physical and
chemical signals, although with it being less clear in many
cases whether P2X3 subunit containing channels are so
intimately involved (reviewed by Housley et al. [133]). In
the visual system, there is clearly immunohistochemical
presence and functional involvement of most ATP receptors
in many cells and functions, but only in a couple of reports
has any evidence been apparent for expression of P2X3
subunits in retinal ganglion cells (among most other P2X
subunits; [134, 135]) and no functional evidence is
apparent. In the olfactory system, it has been established
that both P2Y and P2X receptor activation by ATP reduces
odor responsiveness [136]. Non-selective purinoceptor
antagonists increase the odor-evoked calcium transient,
providing evidence that endogenous ATP down-modulates
odor sensitivity via activation of multiple subtypes in
olfactory receptor neurons; however, the distribution of
P2X3 subunits is limited in olfactory systems, and thus
selective antagonists are unlikely to impart much impact on
sense of smell based on the evidence to date [133].
In the auditory system, there is somewhat greater
evidence for the expression and function of P2X receptors
[133], though the major role of ATP in modulating hearing
seems mediated via P2X2 homotrimers. Purinergic signal-
ing appears to be involved in the regulation of hearing
sensitivity especially under conditions of stress, acting via
the P2X2 subtype receptor in tissues lining the endolym-
phatic compartment [133, 137]. ATP may be a neuro-
modulator at the primary synapse between the inner hair
cell and auditory afferent neurons and a neurotransmitter at
the type II synapse with the outer hair cells which regulates
the generation of spontaneous neural activity in the
developing cochlea, though again any pivotal involvement
of P2X3 subunits has not been shown. ATP may be
involved in neurite growth in primary afferent neurons
and synaptogenesis of the primary synapses, with action via
P2X3 containing receptors, the expression of which follows
development and maturation of the synapse in the rat and
mouse [138–140]. It is not clear whether these possible
actions of ATP at P2X3 containing receptors would
manifest noticeable changes to hearing as a result of
selective antagonism or whether any potential for benefit
could arise.
In the gustatory system, ATP undoubtedly plays a role in
signaling between most oral and post-oral taste buds and
the gustatory C-fibers that innervate them. Studies using
P2X gene deletion mice developed at Roche [38, 39] have
illustrated that absence of both P2X2 and P2X3 subunits
(double KO mice) almost abolishes taste transmission (in
the chorda tympani and glossopharyngeal nerves) and
discriminatory behavior, examining sweet, bitter, salty, sour
and umami tastants [141, 142]. The near abolition of tastant
sensitivity in the double KO mice was only marginally
manifested however, when looking at gustatory nerve
recordings or discriminative two-bottle preference tests in
single P2X3 or P2X2 KO mice, suggesting that channel
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redundancy operates in the transduction of taste bud
responses. Subsequently, the phenotype of the P2X2 and
P2X3 double KO mice has been elucidated further, and
it now appears that the near complete loss of gustatory
function occurred not solely due the absence of C-
afferent ATP receptors, as the pannexin channel release
of ATP from taste buds themselves was eliminated in
the double [143] but not single KO mice. As P2X2 but
not P2X3 receptor subunits are present on taste buds, it
seems that the elimination of P2X3 subunits may blunt but
is unlikely to totally impair taste perception. As antago-
nism of P2X3 and P2X2/3 trimers will not impair function
at homomeric P2X2 receptors on both taste buds and
gustatory C-afferents, the net impact of antagonism is
difficult to predict, and has not been studied using
selective antagonists in rodent models. In fact, earlier
pharmacological exploration in rat isolated tongue–nerve
preparations [144] had indicated limited impact on tastant
sensitivity.
In the craniofacial circuitry, P2X3 expression and
responses are seen in cranial afferents, particularly relating
to the trigeminal ganglia and innervation of dental pulp,
skin, muscle (e.g., masseter) and temporo-mandibular joint
(TMJ), as well as dural afferents with relevance to headache
and migraine. P2X3 receptors are fairly prominently
expressed (30–60% of small- and medium-sized afferents),
and are upregulated following nerve injury or inflammation
in essentially all of these receptive fields, both in small
fibers that are labeled by the isolectin IB4 as well as
medium-sized afferents not bound by this probe [145–152].
Fewer pharmacological studies have been undertaken,
though findings have implicated P2X3 and P2X2/3 receptor
activation in trigeminal neuralgia, TMJ syndrome, burning
mouth syndrome, dental pain and migraine. In the particular
case of migraine, significant interplay between nerve
growth factor, substance P, CGRP and P2X3 has been
detailed [153–156], which may indicate a degree of
regulatory differentiation from DRG circuits where the
functional overlap of P2X3 and peptide containing afferents
seems more limited. Clearly, this is an area which is worthy
of additional focus to understand whether P2X3 antagonists
might have some applicability in craniofacial pain syn-
dromes or even headache, where unmet need persists and
options are sparse.
Another area of emerging interest in the P2X3 field
cover the sensory responses to ischemia in various tissues
and ischemia-associated reflexes that may be evoked or
altered in cardiovascular or skeletal circuits. There is a basis
to suspect that ATP is released in fairly copious amounts
from cells subjected to acute or chronic conditions of
ischemia [157–162], and this has been shown in the context
of ischemia of cardiovascular tissue as well as skeletal
muscle. In the context of cardiac and vascular reflexes, Xu
et al. [163] reported that in the dog, ATP triggers a cardio-
cardiac vagal depressor reflex by activating presumed
P2X2/3 receptors (based on sensitivity to antagonism by
TNP-ATP, and lack of desensitization) found on vagal
sensory terminals in the left ventricle. These authors
suggested that these reflexes may contribute to vasovagal
syncope, intimating a role for extracellular ATP in this
syndrome and that endogenous ATP released from
ischemic cardiomyocytes may be a mediator of atropine-
sensitive bradyarrhythmias associated with left ventricular
myocardial infarction.
Stellate ganglion (SG; sympathetic) cardiac afferents
were studied in a rat myocardial ischemia model [164], and
P2X3 labeling intensity and the P2X3 fiber proportion in
SG were enhanced, suggesting the involvement of P2X3
receptors in sensory transmission after myocardial ischemic
injury. This has since been characterized with similar
findings in parasympathetic nodose afferents [165]. This
group subsequently confirmed that P2X3 receptors mediate
ischemic nociceptive signaling by showing sensitivity of
SG responses to A-317491 [166], and that blocking P2X3
receptors in this model in vivo led to reduced evidence of
cardiac dysfunction, arrhythmia and injury [167] as well as
antagonism of increased sympathoexcitatory reflexes [168].
Fu and Longhurst [169] have extended such observations of
sympathetic cardiac afferents in rat, showing that during
ischemia, endogenously released ATP activates ischemia-
sensitive, but not ischemia-insensitive, cardiac spinal
afferents through stimulation of P2 receptors likely located
on the cardiac sensory neurites, though lacking conclusive
evidence for P2X3 involvement. Developing this line of
pursuit further, it has been reported recently [170] that cardiac
spinal (sympathetic) afferents are excited by ischemic
metabolites and elicit an excitatory sympathetic reflex which
plays a major role in the genesis of ventricular arrhythmias.
Subjecting rats to cardio-spinal deafferentation, disrupted this
reflex offered protection against ischemia-induced ventricu-
lar arrhythmias, and was associated with a reduced
cardiac metabolic demand (lower rate-pressure product and
ST segment elevation) during brief myocardial ischemia.
The exercise pressor reflex (EPR) is a homeostatic
reflex composed of a mechanoreflex and a metaboreflex
in normal healthy individuals, and represents another
afferent activated system that may impinge upon fibers
that express P2X3 receptors, with evidence for greater
contribution in disease [171]. During sustained skeletal
muscle work, as well as in models where blood flow to
skeletal muscles is impaired, an exercise pressor reflex is
triggered. This important reflex is activated during
contraction of muscle primarily by stimulation of “ergo-
receptive” (as opposed to nociceptive) afferent fibers
responsive to either mechanical distortion (so-called group
3 fibers) and/or the metabolic by-products of skeletal
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muscle work (group 4 fibers). EPR is known to be
accentuated in patients with cardiovascular disease (such
as heart failure, hypertension) as it is in rats with muscle
or cardiac ischemia, leading to inappropriately exagger-
ated reflex pressor and tachycardia responses, and poor
tolerance of exercise [171–173]. It is postulated that
heightened mechanoreflex (group 3) and attenuated
metaboreflex (group 4) activity may underlie such changes
[171]. ATP release [162], coupled with upregulation and
activation of P2X3 receptors (probably in concert with
other candidate “metaboreflex” receptors such as TRPv1,
ASIC3) contributes to these exaggerated reflexes [174,
175] and P2X3 receptors may contribute to accentuation
of the sensitivity of the group 3 (purportedly mechanor-
eceptive) fibers [176]. However, it is worth noting that
some ischemic responses induced by ATP release from
myocardial and skeletal muscle tissues are not P2X3
dependent; for example, the study by Birdsong et al. [161]
elegantly described how ATP increased the pH sensitivity
of acid-sensing ion channel 3 (ASIC3), the sensory
receptor for lactic acidosis, via what appears to be a
population of C-afferent P2X5 receptors. Furthermore,
most data supporting P2X3 involvement in EPR stem
from studies in decerebrate animals, and one may ask how
functionally relevant this is for the EPR in intact animals
let alone in healthy humans and heart failure patients. It
will be also interesting to understand whether the chronic
benefits of exercise to reduce EPR in ischemic rats [176]
is itself associated with any change in expression or
function of P2X3 receptors.
Taken together, this varied collection of reports from
investigations of integrated cardiovascular reflexes indi-
cates that ATP signaling is heightened as a consequence of
fatigue and ischemia in skeletal and cardiac muscles, and
that this is associated also with an increased expression and
function of P2X receptors—including P2X3—on sympathetic
and parasympathetic sensory neurons. It appears that this
heightened sensitivity to ATP in ischemic disease may lead
not only to increasing fatigue and declining performance, but
potentially can exacerbate cardiovascular outcomes. In
patients with heart failure, there is intolerance to exercise
reflected by dyspnea, hyperventilation, increased sympathetic
drive, and hypertension that in turn increase risk of stroke and
lethal arrhythmias [177]. Given these P2X3 connections to
pathological reflexes, coupled with the potentially deleteri-
ous role P2X3 activation may have in the airways directly
(see above), selective antagonism of P2X3 containing
receptors may offer utility in suppressing a variety of
co-conspiring inappropriate reflexes and provide new
therapeutic avenues in these conditions with significant
morbidity and unmet need. An agent that can stifle the
exaggerated EPR in patients with cardiorespiratory
disease and suppress the exercise-limiting sequela of
dyspnea could offer some unique benefits. Clearly, an
important question that remains to be elucidated is the
extent to which P2X3 dependent C-afferent pathways
contribute to physiological reflexes versus the patho-
physiological reflexes mentioned above.
Drug discovery achievements
Prior to 2000, there were no reports of “drug-like” small
molecules that selectively antagonized the activation of
P2X3-containing receptors by ATP. Existing antagonists
were large polyanions (e.g., suramin, PPADS) with little
specificity or nucleotides (TNP-ATP), neither of which
provided ideal starting points for medicinal optimization
(Fig. 9). More promising leads were then reported and
patented by Abbott, including A-317491, which offered
submicromolar potency, competitive and selective antago-
nism at P2X3 and P2X2/3 receptors, and with properties
that could offer applicability for in vivo studies in sensory
models. However, these compounds (tricarboxylic acids)
were still polyanions, and despite good plasma half-life in
vivo, A-317491 was almost completely protein bound and
had essentially no permeability from enteric into systemic
compartments or from systemic to central. Despite consider-
able effort, this class of competitive ATP antagonists could not
be optimized chemically into suitably developable small
molecule candidates as the removal of these highly acidic
residues presumably led to loss of activity [61, 178].
The first patents and publications that suggested potential
for drug-like chemistry emerged from Roche Pharmaceuticals
from 2004 onwards. Several novel classes of compounds,
operating non-competitively with ATP, were optimized for
antagonistic potency at P2X3 and P2X2/3 receptors, elabo-
rating chemotypes more compatible with medicinal optimi-
zation and revealing the presence of multiple binding sites,
allotopic to the nucleotide binding site, at which selective
inhibition could be imparted. Several distinct chemical
scaffolds were identified with activity at one or more of these
P2X3 receptor related sites, and thousands of compounds
were directly synthesized to optimize within these classes.
Many potentially developable medicinal candidates of high
potency and selectivity with favorable physicochemical,
pharmacokinetic, toxicological and in vivo pharmacological
profiles have been generated. Likewise, several other compa-
nies identified potentially developable molecular scaffolds,
some similar to as well as distinct from those identified at
Roche, including Evotec (previously Renovis), Astra-Zeneca,
Merck, and Shionogi (see Fig. 9 for several key chemical
examples).
A brief insight into the chemistry related to two of the
Roche chemical scaffolds - the diaminopyrimidines (DAPs)
and substituted arylamides (SAAs), follows. In each case,
the chemical starting point was identified by high-
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throughput screening (HTS) of the vast Roche compound
collection. Low affinity inhibitors (leads) were confirmed
from a diverse (though very low percentage) number of
compound hits from assays conducted at 10 μM at recombi-
nant human P2X3 (DAPs) and P2X2/3 (SAAs) receptors.
These assays made use of fluorometric imaging plate readers
(FLIPR) running in 96 or 384 well capacity, screening ATP or
α,β-methylene ATP (α,β-MeATP) activation of cells loaded
with the Ca++ selective dye Fluo-3. Compounds were
likewise profiled for selectivity by comparison of activity at
P2X1, P2X2, P2X4, P2X5, and P2X7 receptors (at which all
compounds tested were remarkably inactive), in addition to
standard profiling in CEREP (GPCRs, ion channels,
enzymes) and Ambit (kinases) batteries.
As lead optimization continued, most attractive candi-
dates were tested for activity at native P2X3 containing
channels, studying inhibition of ATP or α,β-MeATP
excitation of isolated DRG or nodose ganglion cells by
patch clamp electrophysiology, followed by assessment of
effect in vivo in a range of models of nociception (acute,
chronic, inflammatory, and neuropathic) and visceral
sensitization. The most attractive leads were then assessed
for in vitro and in vivo safety and PK desirability before
advancing for chemical scale up and more thorough
assessment for developability.
A) DAPs
The chemical starting point (a confirmed HTS “hit”) for the
DAP series came from a series of compounds generated at
Hoffmann-La-Roche (Basel) in the early 70s to explore
structure activity relationships (SAR) of congeners of the
bacterial dihydrofolate reductase (DHFR) inhibitor trimeth-
oprim, long used as an antibacterial. The hit DAP
Compound had an IC50 of 1.2 μM at P2X3 receptors.





















































Fig. 9 Chemical structures of various key compounds that antagonize
P2X3 containing receptors: a AF-001 (original DAP HTS “hit”, P2X3
IC50 1.4 μM); b trimethoprim (inactive at 30 μM); c AF-130 (RO-13;
100 nM); d AF-010 (RO-10; 40 nM); e AF-353 (RO-4; 6 nM); f AF-
906 (RO-51; 2 nM); g AF-454 (original SAA HTS “hit”, 0.65 μM) ;
H, AF-014 (3 nM); I, MK-3901 (Merck lead published at ACS 2011;
24 nM)
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Roche collection as well as trimethoprim itself were seen to
be completely inactive at 10 μM, providing early evidence
of tight requirements in SAR.
Key advances in the SAR came from (a) adding the
2-isopropyl (though propyl, t-butyl, and methoxy were all
inactive), (b) replacing the carbon linker between aryl and
DAP groups with oxygen (where greater H-bonding
reduced the available conformations) and, (c) substituting
various subgroups on the aryl 4 and 5 positions to enhance
potency and metabolic stability. A range of 5-substitued
analogs were generated with varied physicochemical
properties (particularly clogP and polar surface area) that
were likely to impact permeability (from gastrointestinal
tract and into CNS), metabolic clearance route, and potency,
with several compounds developed as pharmacological tools
as well as developable medicinal candidates. Of these, AF-
010 (5-MeO), AF-130 (5-SO2Me), AF-353 (5-I; previously
RO-4) and AF-792 (5-acetylene) have been well described in
literature [2, 61, 179–181]. The clinical lead compound, AF-
219, is a very close analog of these and was advanced into
development having best satisfied the required characteristics
for development.
B) SAAs
The chemical starting point for the SAA series emerged from a
FLIPR based library screen at the heterotrimeric P2X2/3
receptor, and was a unique compound in the Roche library
(singleton), and turned out to be structurally related to a lead
subsequently identified at Merck. Greater chemical latitude
for optimization was apparent based on pharmacophore
models within this chemotype that have since been iteratively
developed, both at Roche [182, 183] and Merck [184],
leading to many potent, selective, and biologically active
antagonists that also represent candidates for medicinal
development and have shown activity in a range of sensory
models in vivo. Figures 9 shows examples of potent
optimized lead molecules from the SAA chemical series,
all displaying potencies in the 3–100-nM range at P2X3
containing receptors with no activity at concentrations below
10 μM at other P2X receptors, nor at a wide range of
classical transmitter receptors, enzymes, channels, and
kinases. The properties of a lead compound from Merck's
SAA optimization were recently disclosed (ACS meeting,
Anaheim, March 2011), MK3901 being described as a
potent, selective CNS-penetrant P2X3 antagonist (IC50
∼23 nM) with activity in CFA, mIOA, and Chung (SNL)
models of inflammatory and neuropathic pain.
Drug development
Afferent Pharmaceuticals, which licensed the P2X3 antag-
onist program from Roche in 2009, is currently advancing
several compounds through early development phases. The
clinical lead compound, AF-219, is a DAP series member
close in structure to the 5-aryl substituted compounds
shown in Fig. 9. AF-219 has completed IND-enabling GLP
safety studies and three phase 1 studies in normal healthy
volunteers. The compound is being developed as a twice
daily, oral tablet, and has shown excellent safety and
tolerability in clinical studies to date, with exposures
achieved that significantly exceed those projected to fully
engage the target and shown effective in preclinical rodent
models, as well as showing activity in a clinical biomarker
provocation assay. A series of phase 2 “POC” studies has
now been initiated, with data anticipated in 2012 in several
patient populations, designed to explore indications where
blockade of P2X3 containing receptors may offer best
clinical utility: these include joint pain (OA of the knee),
visceral pain (BPS/IC), and airways sensitization (chronic
idiopathic cough). Additional studies in other types of pain
utility of will also be considered. This breadth of approach
reflects (a) the wide range of tissues and clinical situations
where ATP signaling has been reported to contribute to
sensitization in chronic pathology through direct effect on
sensory fibers, (b) the extensive evidence presented from
rodent studies in KO mice (gene-deletion mutants), anti-
sense/RNAi investigations as well as studies using small
molecule probes, and, (c) the historical opportunities and
threats observed in effectively translating novel sensory
targeted interventions into the clinical realm.
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